Viva Biotech Holdings disclosed its Monthly Return for Equity Issuers for the period ended 31 January 2026, confirming a steady capital structure and compliance with Hong Kong Stock Exchange public-float rules.
Authorised and Issued Share Capital • Authorised share capital closed the month unchanged at 4.00 billion ordinary shares with a par value of USD 0.000025 each, representing total authorised capital of USD 100,000.
• Issued share capital remained stable at 2.13 billion ordinary shares. The company held no treasury shares, and there were no new share issues, cancellations or repurchases during the month.
Public-Float Compliance Viva Biotech affirmed that it met the Main Board’s minimum public-float requirement of 25% as of 31 January 2026.
Share Option Activity • Pre-IPO Share Incentive Schemes: 2.22 million options remained outstanding, unchanged month-on-month. No options were exercised, cancelled or lapsed.
• Post-IPO Share Option Scheme: Outstanding options decreased from 18.12 million to 13.70 million after 4.42 million options lapsed. No new options were granted or exercised. The scheme still allows for up to 124.35 million shares to be issued upon future grants.
Fund-Raising and Other Instruments No funds were raised through option exercises, and there were no outstanding warrants, convertible securities, or other equity-linked arrangements reported for the month.
Governance Confirmation Executive Director Mao Chen Cheney confirmed that all share-related activities complied with HKEX listing rules and relevant legal requirements.
Comments